Ocuphire Pharma, Inc. (OCUP)
NASDAQ: OCUP · IEX Real-Time Price · USD
1.990
+0.050 (2.58%)
At close: Jul 19, 2024, 4:00 PM
1.940
-0.050 (-2.51%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Ocuphire Pharma Revenue
Ocuphire Pharma had revenue of $19.01M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $1.71M. In the year 2023, Ocuphire Pharma had annual revenue of $19.05M.
Revenue (ttm)
$19.01M
Revenue Growth
-54.30%
P/S Ratio
2.71
Revenue / Employee
$1,357,929
Employees
14
Market Cap
51.59M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
Dec 31, 2021 | 589.00K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 75.00K | - | - |
Dec 31, 2007 | 75.00K | - | - |
Dec 31, 2006 | 75.00K | - | - |
Dec 31, 2005 | 75.00K | - | - |
Dec 31, 2004 | 75.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Inotiv | 552.74M |
Cidara Therapeutics | 46.38M |
Atara Biotherapeutics | 34.70M |
LAVA Therapeutics | 13.63M |
vTv Therapeutics | 1.00M |
Barinthus Biotherapeutics | 334.00K |
OCUP News
- 12 days ago - Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July - GlobeNewsWire
- 6 weeks ago - Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June - GlobeNewsWire
- 2 months ago - Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Ocuphire Pharma to Present at the Aegis Virtual Conference - GlobeNewsWire
- 3 months ago - Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting - GlobeNewsWire
- 3 months ago - First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery - GlobeNewsWire
- 4 months ago - Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris - GlobeNewsWire